Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: Meta-analysis of randomized controlled trials

Radiology

Volumn 250, Issue 1, 2009, Pages 68-86

  Heinrich, Marc C ^a   Häberle, Lothar ^a   Müller, Volker ^b   Bautz, Werner ^a   Uder, Michael ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CREATININE; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXAGLIC ACID; NONIONIC CONTRAST MEDIUM; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IOBITRIDOL; IODOBENZOIC ACID DERIVATIVE;

ANGIOCARDIOGRAPHY; ARTERIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIAGNOSTIC IMAGING; DIALYSIS; HIGH RISK PATIENT; HUMAN; HYDRATION; KIDNEY FAILURE; META ANALYSIS; NEPHROTOXICITY; OSMOLALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; ACUTE KIDNEY FAILURE; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CONFIDENCE INTERVAL; FEMALE; HEART CATHETERIZATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; OSMOLARITY; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; CONFIDENCE INTERVALS; CONTRAST MEDIA; CREATININE; FEMALE; HEART CATHETERIZATION; HUMANS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; IOHEXOL; IOPAMIDOL; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TOMOGRAPHY, X-RAY COMPUTED; TRIIODOBENZOIC ACIDS;

EID: 58149331038     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2501080833     Document Type: Article

References (74)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
2. Katzberg RW, Haller G. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl 2006;100:S3-S7.
3. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-1783.
4. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;273:1489-1494.
5. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-294.
6. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;334:379-386.
7. Marenzi G, Assanelli E, Marana I, et al. N-acetyl cysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
8. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295:2765-2779.
9. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
10. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation 2007; 116:el48-e304. http://circ.ahajournals.org/cgi/reprint/116/7/803. Accessed August 24, 2007.
11. Thomsen HS, Morcos SK. Contrast-medium-induced nephropathy: is there a new consensus? a review of published guidelines. Eur Radiol 2006;16:1835-1840.
12. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007;115:3189-3196.
13. Sandler CM. Contrast-agent-induced acute renal dysfunction - is iodixanol the answer? N Engl J Med 2003;348:551-553.
14. Thomsen HS, Morcos SK, Erley CM, et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 2008;43:170-178.
15. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006;41:815-821.
16. Higgins JPT, Green S, eds. Locating and selecting studies. Section 5. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 4.2.6. http://www.cochrane.org/resources/nandbook/hbook.htm. Updated September 2006. Accessed January 20, 2007.
17. Solomon R, Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney Int Suppl 2006;100:S46-S50.
18. Jadad AR, Moore RA, Carroll D, et al. As sing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
19. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-178.
20. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2003;68:2236-2263.
21. Solomon R, Dumouchel W. Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 2006;41:631-660.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:337-360.
24. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;332:609-613.
25. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1359-1573.
26. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
28. Deeks JJ, Higgins JPT, Altman DG, eds. Analysing and presenting results. Section 8. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 4.2.6. http://www. cochrane.org/resources/handbook/ hbook.htm. Updated September 2006. Accessed January 20, 2007.
29. Tytle T, Prati RC Jr, Azodo MV, Gutierrez O. A prospective, parallel, double-blind comparison of iodixanol and iohexol in extremity phlebography. Acad Radiol 1996;3(suppl 3):S519-S523.
30. Poirier VC, Monsein LH, Newberry PD, Kreps BJ. Double-blind, randomized comparison of iodixanol 320 and iohexol 300 for cerebral angiography. Invest Radiol 1994;29(suppl 2):S43-S44.
31. Grossman RI, Modic MT. A randomized comparison of iodixanol and iohexol in adult intracranial computed tomography scan ning. Acad Radiol 1996;3(suppl 3):S488-S494.
32. Kuhn MJ, Chen N, Sahani D, et al. The PREDICT study: a randomized, double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 2008;191:151-157.
33. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications 2008;22:171-177.
34. Schmid I, Didier D, Pfammatter T, et al. Effects of non-ionic iodinated contrast media on patient heart rate and pressures during intracardiac or intra-arterial injection. Int J Cardiol 2007;118:389-396.
35. Feldkamp T, Baumgart D, Eisner M, et al. Nephrotoxicity of isoosmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol 2006;66:322-330.
36. Rudnick M. Clinical consequences of contrast nephropathy. Presented at the Official Luncheon Symposium, Contrast Induced Nephropathy (GIN): Clinical Significance and Prevention, American Society of Nephrology, Philadelphia, Pa, November 10, 2005.
37. Solomon R, Rudnick M. Let the data decide. Imaging Econ 2007;May(suppl):S13-S18.
38. Sinha SK, Berry WAD, Bueti J, et al. The Prevention of Radiocontrast-induced Nephropathy Trial (PRINT): a prospective, double-blind, randomized, controlled trial of isoosmolar versus low-osmolar radiocontrast in combination with n-acetylcysteine versus placebo [abstr]. Circulation 2004;110(suppl 5):377.
39. Kolehmainen H, Soiva M. Comparison of Xenetix 300 and Visipaque 320 in patients with renal failure [abstr]. Eur Radiol 2003;13(suppl):B32-B33.
40. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701-703.
41. Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998;8:144-147.
42. Siegle RL, Gavant ML. Comparison of iodixanol with iohexol in excretory urography. Acad Radiol 1996;3(suppl 3):S524-S527.
43. Lee FT Jr, Caroline DF, Thornbury JR, et al. A randomized comparison of iodixanol and iohexol in adult body computed tomography scanning. Acad Radiol 1996;3(suppl 3): S500-S506.
44. Jakobsen JA, Berg KJ, Kjaersgaard P, et al. Angiography with nonionic x-ray contrast media in severe chronic renal failure: renal function and contrast retention. Nephron 1996;73:349-556.
45. Fischbach R, Landwehr P, Lackner K, et al. Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-Ill trial. Eur Radiol 1996;6:9-13.
46. Manninen H, Tahvanainen K, Borch KW, et al. Iodixanol, a new non-ionic, dimeric contrast medium in cardioangiography: a double-masked, parallel comparison with iopromide. Eur Radiol 1995;5:384-370.
47. Verow P, Nossen JO, Sheppick A, Kjaersgaard P. A comparison of iodixanol with iopamidol in aorto-femoral angiography. Br J Radiol 1995;88:973-978.
48. Flinck A, Selin K, Bjorneld L, Nossen JO. Iodixanol and iohexol in cardioangiography: a comparative vectorcardiographic study. Acta Radiol 2000;41:384-389.
49. Flinck A, Selin K, Bjorneld L. Iodixanol in cardioangiography [abstr]. Acta Radiol Suppl 1994;35(suppl 394):39.
50. Thorstensen O, Aforechtsson U, Calissendorff B, et al. Iodixanol in femoral arteriography: a randomized, double-blind, phase HI, parallel study with iodixanol 270 mg I/ml and iohexol 300 mg I/ml. Acta Radiol 1994;35:629-631.
51. Hill JA, Cohen MB, Kou WH, et al. Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography. Am J Cardiol 1994;74:57-63.
52. Singh K, Sundgren R, Bolstad B, Bjork L, Lie M. Iodixanol in abdominal digital subtraction angiography: a randomized, double-blind, parallel trial with iodixanol and iohexol. Acta Radiol 1993;34:242-245.
53. Pugh ND, Sissons GR, Ruttley MS, Berg KJ, Nossen JO, Eide H. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol 1993;47:98-99.
54. Klow NE, Levorstacl K, Berg KJ, et al. Iodixanol in cardioangiography in patients with coronary artery disease: tolerability, cardiac and renal effects. Acta Radiol 1993;34:72-77.
55. Grynne BH, Nossen JO, Bolstad B, Borch KW. Main results of the first comparative clinical studies on Visipaque. Acta Radiol Suppl 1995;399:265-270.
56. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006;48:892-699.
57. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000;101:2172-2177.
58. Sharma SK, Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv 2005;65:386-393.
59. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial - the Iohexol Cooperative Study. Kidney hit 1993;47:254-261.
60. Heinrich M, Scheer M, Heckmann M, Bautz W, Uder M. Reversibility and time-dependency of contrast medium induced inhibition of 3-(4,5-Dimethylthiazol- 2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) conversion in renal proximal tubular cells in vitro: comparison of a monomeric and a dimeric nonionic iodinated contrast medium. Invest Radiol 2007;42:732-738.
61. Seeliger E, Flemming B, Wronski T, et al. Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol 2007;18:2912-2920.
62. Heinrich MC, Kuhlmann MK, Kohlbacher S, et al. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Radiology 2007;242:425-434.
63. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235:843-849.
64. Donadio C, Lucchesi A, Ardini M, et al. Renal effects of cardiac angiography with different low-osmolar contrast media. Ren Fail 2001;23:385-396.
65. Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. Am J Physiol Renal Physiol 2001;280:F61-F70.
66. Almen T. Contrast media: the relation of chemical structure, animal toxicity and adverse clinical effects. Am J Cardiol 1990;66:2F-8F.
67. Schick CS, Haller C. Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro. Nephrol Dial Transplant 1999;14:342-347.
68. Briguori C, Colombo A, Airoldi F, et al. Nephrotoxicity of low-osmolality versus iso osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2003;68:2230-2255.
69. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989;320:143-149.
70. Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15:349-354.
71. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
72. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
73. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95:13-19.
74. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006;186:161-168.